Role of the nitric oxide-cyclic GMP-K+ channel pathway in the antinociception induced by atrial natriuretic peptide (ANP) and diclofenac

Proc West Pharmacol Soc. 2002:45:174-7.
No abstract available

MeSH terms

  • Analgesics / pharmacology*
  • Animals
  • Anti-Inflammatory Agents, Non-Steroidal / pharmacology*
  • Atrial Natriuretic Factor / pharmacology*
  • Charybdotoxin / pharmacology
  • Cyclic GMP / metabolism
  • Cyclic GMP / physiology*
  • Diclofenac / pharmacology*
  • Dose-Response Relationship, Drug
  • Enzyme Inhibitors / pharmacology
  • Female
  • Formaldehyde
  • Glyburide / pharmacology
  • NG-Nitroarginine Methyl Ester / pharmacology
  • Nitric Oxide / antagonists & inhibitors
  • Nitric Oxide / physiology*
  • Nitric Oxide Synthase / antagonists & inhibitors
  • Oxadiazoles / pharmacology
  • Pain Measurement / drug effects
  • Potassium Channels / physiology*
  • Quinoxalines / pharmacology
  • Rats
  • Rats, Wistar
  • Tolbutamide / pharmacology

Substances

  • 1H-(1,2,4)oxadiazolo(4,3-a)quinoxalin-1-one
  • Analgesics
  • Anti-Inflammatory Agents, Non-Steroidal
  • Enzyme Inhibitors
  • Oxadiazoles
  • Potassium Channels
  • Quinoxalines
  • Charybdotoxin
  • Diclofenac
  • Formaldehyde
  • Nitric Oxide
  • Atrial Natriuretic Factor
  • Tolbutamide
  • Nitric Oxide Synthase
  • Cyclic GMP
  • Glyburide
  • NG-Nitroarginine Methyl Ester